Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

37 results about "Colorectal adenocarcinoma" patented technology

Method And Apparatus To Diagnose The Metastatic Or Progressive Potential Of Cancer, Fibrosis And Other Diseases

A method and apparatus for determining the progressive potential of a disease is disclosed. The forward to backward propagating second harmonic generation signal derived from a second harmonic generation instrument is used to assess the collagen microstructure of imaged body tissue by way of numerical values that are in turn used to determine the progressive or metastatic potential of the disease. The disease may, for example, be a cancer such as breast cancer, lung fibrosis, colorectal adenocarcinoma, or the like. The apparatus may include in vivo instruments or laboratory diagnostic instruments with methods disclosed herein.
Owner:UNIVERSITY OF ROCHESTER

Quinoline multi-target kinase inhibitor with antitumor activity and preparation method thereof

The invention relates to a quinoline multi-target kinase inhibitor with antitumor activity and a preparation method thereof. A general structural formula of the compound is shown in a formula (I) described in the specification. In vitro cell experiments verify that the compound provided by the invention has strong in vitro inhibitory activity on five common tumor cell lines, namely human thyroid carcinoma SW579, human hepatic carcinoma HepG2, human lung adenocarcinoma A549, human colorectal adenocarcinoma HCT116 and human gastric carcinoma MKN45, antitumor activities of most of target compounds are better than or equivalent to that of a positive control drug Cabozantinib, and the in vitro cell experiments verify that the compound provided by the invention has strong inhibitory activity on two kinases KDR and MET, so that the compound provided by the invention has a broad application prospect in preparation of a new antitumor drug.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY

Fructus terminaliae billericae extract with anti-cancer effect, and preparation method of effective part of fructus terminaliae billericae extract

The invention relates an anticancer active part of fructus terminaliae billericae, and a preparation method of the anticancer active part. The invention comprises extraction of the part containing active components, study of a process for enriching by adopting macroporous absorption resin, identification of the active components in the active part, and use of the active part in in-vivo or in-vitroinhibition of liver cancer HepG2, lung cancer A549, lung adenocarcinoma NCI-H1703, gastric cancer BGC823, osteosarcoma cell MG-63, colorectal cancer HCT116, breast cancer MCF-7, neuroblastoma cells shsy5y, kidney cancer ACHN, normal liver cells L02, human breast ductal carcinoma cells ZR75-1, human colorectal adenocarcinoma cells Colo-205, human breast ductal carcinoma cells BT-474, human breastcancer cells T-47D, human cervical cancer cell line HeLa, liver cancer cells H22, and the like. The enrichment method applying the macroporous absorption resin to the anti-cancer active part of the fructus terminaliae billericae is simple in process, safe, non-toxic and low in production cost, and can be used for industrial production, thus having a great economic benefit and higher generalizationperformance.
Owner:BEIJING UNIV OF CHINESE MEDICINE

5,8-disubstituted-1,6-quinazoline-7-amidocarbonylation compound, preparing method, composite and application thereof

The invention discloses a 5,8-disubstituted-1,6-quinazoline-7-amidocarbonylation compound, a preparing method, an application and a drug composite containing the compound thereof. More specifically, the invention discloses a 5,8-disubstituted-1,6-quinazoline-7-amidocarbonylation compound as shown in the formula I, a preparing method and an application thereof. By the growth inhibition test of various tumour cell lines (human breast cancer cells MDA-MB-435, p53-deleted poorly differentiated colorectal adenocarcinoma cells Hct116p53- / -, p53-enriched poorly differentiated colorectal adenocarcinoma cells Hct116p53+ / +, human breast cancer cells Mcf-7, NIH189, human breast cancer cells SkBr-3, prostatic cancer cells LnCap, LnHer, human colorectal cancer cells HT29 and human ovarian cancer cellsHEY), the compound has favourable inhibition activity for the above tumour cells and can treat diseases caused by tumour cell malignant proliferation. The invention also discloses a drug composite containing the compound.
Owner:SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI

Method for determining APRIL (A Proliferation-inducing Ligand) gene promoter and transcription factor binding site and use

The invention discloses a method for determining an APRIL (A Proliferation-inducing Ligand) gene promoter and transcription factor binding site and use. According to the invention, a promoter region of APRIL is cloned and identified. As discovered, a region from -1539 to -1001 has an important effect on transcription adjustment and control over APRIL; a transcription factor Sp1 or NF-kB exits in the region; and the transcription of the APRIL gene can be activated. The invention provides application of mithramycin and Bay11-7082 to preparation of medicaments for treating human colorectal adenocarcinoma; and the effect is clear.
Owner:AFFILIATED HOSPITAL OF NANTONG UNIV

Methods and compositions for diagnosing and treating a colorectal adenocarcinoma

The present invention relates to in vitro methods and compositions for diagnosing and / or treating a colorectal adenocarcinoma associated with a chromosomal aberration on chromosome 20q and / or the predisposition for developing such an adenocarcinoma by determining the expression levels of a set of particular marker genes, wherein an elevated expression level of the marker genes in a test sample as compared to a control level is indicative of a colorectal adenocarcinoma.
Owner:VER VOOR CHRISTELIJK HOGER ONDERWIJS WETENSCHAPPELIJK ONDERZOEK & PATIENTENZORG

Co-containing sandwich heteropolyacid as well as synthesis method and application thereof

The invention discloses Co-containing sandwich heteropolyacid as well as a synthesis method and application thereof, relating to heteropolyacid as well as synthesis method and application thereof. The invention provides a novel chemotherapy drug capable of resisting human colorectal adenocarcinoma and a synthesis method thereof. The molecular formula of the Co-containing sandwich heteropolyacid provided by the invention is H6[Bi2W20Co2(OH2)6O70Na4(OH2)14](C3H4N2)2. The synthesis method is as follow: firstly, dissolving Na2WO4 into water, heating and adjusting the pH value to obtain solution A; secondly, dissolving Bi(NO3)3, CoC12 and imidazole into the solution A at the same time to be uniformly mixed; heating to 80-120 DEG C and maintaining the temperature for 1-2h; and cooling, filtering and standing to obtain Co-containing sandwich heteropolyacid. The Co-containing sandwich heteropolyacid has the action of restraining the growth of cancer cells and the action of inducing death of the cancer cells. Therefore, the Co-containing sandwich heteropolyacid can be used as a chemotherapy drug for treatment of human colorectal adenocarcinoma.
Owner:HARBIN INST OF TECH

Antibody for inhibitting growth of colorectal carcinoma and its use in preparation of medicament and kit

The invention provides a monoclonal antibody, which has the following characteristics: 1) the antibody is IgMs immunoglobulin and the light-chain type of the antibody is k-typed; (2) the antigen is identified into a sugar-chain structure with sialylation mucoprotein surface; the monoclonal antibody can specifically identify colorectal adenocarcinoma, endometrial adenocarcinoma and pancreatic carcinoma tissues, can not identify the corresponding normal tissues. Specifically, the monoclonal antibody is formed by the secreting of hybridomas cells with the accession number of CGMCC No. 2643, the amino acid sequence in the heavy-chain variable zone is shown as SEQ ID NO: 1, the amino acid sequence in the light-chain variable zone is shown as SEQ ID NO: 2. The invention also provides a use of the monoclonal antibody in the preparation of a medicament or a kit, wherein the medicament or the kit can be used for the screening of cancer, early-stage diagnosis, treatment monitoring and tumour imaging. In addition, the invention provides a new antibody for inhibitting the growth of the tumor cells of colorectal carcinoma.
Owner:INSITUTE OF BIOPHYSICS CHINESE ACADEMY OF SCIENCES

Traditional Chinese medicine composition and application thereof

The invention relates to a traditional Chinese medicine composition for preventing and treating colorectal adenoma, colorectal adenocarcinoma and relapse after endoscopic resection of colorectal adenoma. The traditional Chinese medicine composition is characterized in that the traditional Chinese medicine composition is prepared from the following main active ingredients in parts by weight: 1-300 parts of poria cocos, 1-300 parts of Chinese yam, 1-300 parts of coix seed, 1-300 parts of Chinese actinidia root, 1-250 parts of duchesnea indica, 1-250 parts of sargentgloryvine stem, 1-250 parts of elecampane and 1-120 parts of honey-fried licorice root. The invention further provides application of the traditional Chinese medicine composition in preparation of medicines for improving immunity of organisms and application of the traditional Chinese medicine composition in preparation of medicines for preventing and treating colorectal adenoma, colorectal adenocarcinoma and relapse after endoscopic resection of the colorectal adenoma.
Owner:段鲜红

Matrine pyrimidine derivative, and preparation method and application thereof

The invention discloses a matrine pyrimidine derivative, and a preparation method and application thereof, and belongs to the technical field of medicinal chemistry. The matrine pyrimidine derivative is a compound represented by a general formula (I) shown in the specification, or a compound represented by a general formula (II) shown in the specification. The matrine pyrimidine derivative disclosed by the invention has certain inhibitory activity on human tumor cells (human prostate cancer cells DU-145, human non-small cell lung cancer cells A549, human colorectal adenocarcinoma cells HCT15 and human cervical carcinoma cells HeLa), so that proliferation and differentiation of the tumor cells can be inhibited, and a new thought is provided for research and development of anti-tumor drugs; and the preparation method disclosed by the invention is simple, convenient and controllable, and the obtained product is high in yield and extremely high in purity.
Owner:GUANGXI UNIV

Preparation method for polypeptide marker Pep5 enzyme-linked immunosorbent assay (ELISA) kit

The invention provides a polypeptide marker Pep5 enzyme-linked immunosorbent assay (ELISA) kit which contains a monoclonal antibody which is labeled by enzyme and secreted by monoclonal antibody hybridoma cell line with a China general microbiological culture collection center (CGMCC) No. 5269. The kit prepared by the monoclonal antibody secreted by the hybridoma cell line can be used for detecting colorectal adenocarcinoma, and is simple, convenient and rapid to operate, beneficial to high flux clinical detection and low in detection cost.
Owner:BEIJING C & N INT SCI TECH +1

DNA methylation in colorectal and breast cancer diagnostic methods

The present invention relates generally to nucleic acid molecules in respect of which changes to DNA methylation levels are indicative of the onset or predisposition to the onset of a neoplasm. More particularly, the present invention is directed to nucleic acid molecules in respect of which changes to DNA methylation levels are indicative of the onset and / or progression of a large intestine or breast neoplasm, such as an adenoma or adenocarcinoma. The DNA methylation status of the present invention is useful in a range of applications including, but not limited to, those relating to the diagnosis and / or monitoring of colorectal or breast neoplasms, such as colorectal or breast adenocarcinomas. Accordingly, in a related aspect the present invention is directed to a method of screening for the onset, predisposition to the onset and / or progression of a neoplasm by screening for modulation in DNA methylation of one or more nucleic acid molecules. The nucleic acid molecules used for diagnostics in the present invention are sequences from LOC 100526820, subsequently named CAHM (colorectal adenocarcinoma hypermethylated).
Owner:CLINICAL GENOMICS PTY LTD +1

Application of magnolin in resisting colorectal cancer

The invention discloses an application of magnolin in resisting colorectal cancer. Magnolin significantly inhibits the growth and proliferation of human colorectal cancer cells and human colorectal adenocarcinoma cells, significantly inhibits the growth of human colorectal cancer, and significantly inhibits the cell cycle of human colorectal cancer; magnolin promotes the autophagy of human colorectal cancer cells and human colorectal cancer. By blocking LIF / Stat3 / Mcl-1 pathways, magnolin can promote the autophagy of the colorectal cancer cells and colorectal cancer, inhibits the proliferationof the colorectal cancer cells and blocks the period of the colorectal cancer cells. Magnolin has the activity of resisting human colorectal cancer cells and human colorectal cancer, and can be used for preparing products for resisting colorectal cancer or resisting the colorectal cancer cells.
Owner:TIANJIN UNIV OF TRADITIONAL CHINESE MEDICINE

DNA methylation in colorectal and breast cancer diagnostic methods

The present invention relates generally to nucleic acid molecules in respect of which changes to DNA methylation levels are indicative of the onset or predisposition to the onset of a neoplasm. More particularly, the present invention is directed to nucleic acid molecules in respect of which changes to DNA methylation levels are indicative of the onset and / or progression of a large intestine or breast neoplasm, such as an adenoma or adenocarcinoma. The DNA methylation status of the present invention is useful in a range of applications including, but not limited to, those relating to the diagnosis and / or monitoring of colorectal or breast neoplasms, such as colorectal or breast adenocarcinomas. Accordingly, in a related aspect the present invention is directed to a method of screening for the onset, predisposition to the onset and / or progression of a neoplasm by screening for modulation in DNA methylation of one or more nucleic acid molecules. The nucleic acid molecules used for diagnostics in the present invention are sequences from LOC 100526820, subsequently named CAHM (colorectal adenocarcinoma hypermethylated).
Owner:CLINICAL GENOMICS PTY LTD +1

Protein-based methods and compositions for the diagnosis of colorectal adenocarcinoma

Protein-based methods and compositions for the diagnosis of colorectal adenocarcinoma are disclosed. A method for identifying cell-surface proteins, which are transmembrane proteins or proteins with a signal peptide and which are over-expressed in colorectal cancer (CRC) is disclosed. Biomarkers found with this method, diagnostic methods using them and contrast agents directed to them for use in magnetic resonance imaging (MRI) and / or magentic photon imaging (MPI) are disclosed. The methods and biomarkers allow for differentiating progressive (high-risk) CRC (adenocarcinomas) from non-progressive (low-risk) colorectal adenomas.
Owner:VER VOOR CHRISTELIJK HOGER ONDERWIJS WETENSCHAPPELIJK ONDERZOEK & PATIENTENZORG

Polypeptide marker Pep5 enzyme-linked immunosorbent assay (ELISA) kit

The invention provides a polypeptide marker Pep5 enzyme-linked immunosorbent assay (ELISA) kit which contains a monoclonal antibody which is labeled by enzyme and secreted by monoclonal antibody hybridoma cell line with a China general microbiological culture collection center (CGMCC) No. 5269. The kit prepared by the monoclonal antibody secreted by the hybridoma cell line can be used for detecting colorectal adenocarcinoma, and is simple, convenient and rapid to operate, beneficial to high flux clinical detection and low in detection cost.
Owner:BEIJING C & N INT SCI TECH +1

Human colorectal adenocarcinoma cell TRPV1 gene knockout cell strain and application

The invention discloses a human colorectal adenocarcinoma cell TRPV1 gene knockout cell strain and application. The cell strain is named as a human colorectal adenocarcinoma cell TRPV1 gene knockout cell strain CACO-2 KO, and was preserved in China Center for Type Culture Collection on December 25, 2019, and the preservation number is CCTCC NO. C202024. According to the invention, based on the CRISPR / cas9 technology, a plasmid vector constructed by using a pair of gRNAs represented by SEQ ID NO: 2-3 is adopted to electrically transfect a cell to be knocked out, and resistance and sequencing screening are performed to obtain the recombinant plasmid vector. The designed gRNA can accurately and efficiently knock out the TRPV1 gene, and a human colorectal adenocarcinoma cell line with the TRPV1 gene knocked out is effectively constructed. The establishment of the TRPV1 gene knockout cell line provides effective gene materials and gene tools for researching the action mechanism of capsaicine.
Owner:SOUTHWEST UNIVERSITY FOR NATIONALITIES

1,7-Meta-dicarbadecaborane diformic acid-triphenyltin chloride complex, as well as preparation method and application thereof

The invention provides a 1,7-meta-dicarbadecaborane diformic acid-triphenyltin chloride complex, as well as a preparation method and application of the 1,7-meta-dicarbadecaborane diformic acid-triphenyltin chloride complex. The molecular formula of the 1,7-meta-dicarbadecaborane diformic acid-triphenyltin chloride complex is {[(Ph3Sn)(m-CDC)}.(2,2'-Bipyridine)}n(m-CDCH2=1,7-meta-dicarbadecaborane diformic acid; the 1,7-meta-dicarbadecaborane diformic acid-triphenyltin chloride complex has high antitumor activity and can be taken as the raw material to prepare drugs for treating leukemia, human colon cancer and human colorectal adenocarcinoma. Compared with the platinum type anti-cancer drugs commonly used at present, the organic tin complex provided by the invention has the advantages such as high antitumor activity, good lipid solubility, low cost and simple preparation method; and as a result, a new thinking and a new method are provided for developing anticancer drugs.
Owner:LIAOCHENG UNIV

Diosgenin hydroxamic acid derivatives as well as preparation method and application thereof

The invention discloses diosgenin hydroxamic acid derivatives as well as a preparation method and application thereof. Diosgenin is used as a lead compound, a series of hydroxamic acid derivatives are prepared through corresponding chemical reactions, and the application of the derivatives in the anti-tumor aspect is also disclosed. Pharmacological experiments show that all the synthesized diosgenin hydroximic acid derivatives are subjected to in-vitro anti-proliferative activity experiments on SW620 (human colonic adenocarcinoma cells), H358 (human non-small cell lung cancer cells), HCT-116 (human colorectal adenocarcinoma cells) and Aspc-1 (human metastatic pancreatic cancer cells) by adopting a CCK8 method. Experimental results show that the anti-tumor activity of most of the derivatives on cells is superior to that of diosgenin.
Owner:SOUTHWEST UNIVERSITY FOR NATIONALITIES

Biological marker for detecting colorectal cancer and application thereof

The invention relates to a diagnostic marker, in particular to a biological marker for detecting colorectal cancer and application thereof. Experiment and study find that a PAPPA (pregnancy-related plasma protein A) gene has obvious difference between the mRNA expression levels in colorectal adenocarcinoma tissues, mucinous colorectal adenocarcinoma tissues, cecal adenocarcinoma tissues, sigmoid colorectal carcinoma tissues and rectal adenocarcinoma tissues and the mRNA expression level in the tissues of healthy reference substances; the PAPPA protein expression level in serum of a colorectalcancer patient is significantly higher than the protein expression level in the serum of a normal person. The biological marker has the characteristics that the correlation between the PAPPA and the colorectal cancer is put forward for the first time; experiment proves that the PAPPA can be used for diagnosing the colorectal cancer; the operation is simple, the specificity is high, and the sensitivity is high.
Owner:江西佰延生物技术有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products